Literature DB >> 29706164

Has the Prevalence of Child and Adolescent Mental Disorders in Australia Changed Between 1998 and 2013 to 2014?

Michael G Sawyer1, Christy E Reece2, Alyssa C P Sawyer2, Sarah E Johnson3, David Lawrence4.   

Abstract

OBJECTIVE: This study examined whether the 12-month prevalence of major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), and conduct disorder (CD) among 6- to 17-year-olds in Australia changed between 1998 and 2013 to 2014. It also investigated whether changes in the prevalence of disorders over this time varied for children living in families containing 2 parents versus single parents, and families with high versus low income.
METHOD: The study used data from national surveys conducted in Australia in 1998 (N = 3,597) and 2013 to 2014 (N = 5,359). In both surveys, the participating individuals were randomly selected from all 6- to 17-year-olds in Australia, and mental disorders were assessed using the Diagnostic Interview Schedule for Children Version IV (DISC-IV), completed by parents.
RESULTS: There was little change in the overall prevalence of mental disorders between 1998 (12.5%, 95% CI = 11.4-13.7) and 2013 to 2014 (11.1%, 95% CI = 10.1-12.2). Although there were some differences in the changes for children with different disorders, most were small in magnitude. Specifically, MDD prevalence increased from 2.1% (95% CI = 1.7-2.7) to 3.2% (95% CI = 2.7-3.8), ADHD prevalence declined from 9.9% (95% CI = 8.9-10.9) to 7.8% (95% CI = 6.9-8.7), and CD prevalence declined from 2.7% (95% CI = 2.2-3.3) to 2.1% (95% CI = 1.7-2.7). There was a persisting pattern of higher prevalence among children living in single-parent and low-income households.
CONCLUSION: Lack of change at a population level in the prevalence of child mental disorders suggests that new innovations in research, policy, and practice are needed to successfully address the major public health problem posed by child and adolescent mental disorders in the community.
Copyright © 2018 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DSM-IV; epidemiology; mental disorders; prevalence

Mesh:

Year:  2018        PMID: 29706164     DOI: 10.1016/j.jaac.2018.02.012

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  14 in total

Review 1.  Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis.

Authors:  Cellina Ching; Guy D Eslick; Alison S Poulton
Journal:  JAMA Pediatr       Date:  2019-07-01       Impact factor: 16.193

2.  Age-varying associations between lifestyle risk factors and major depressive disorder: a nationally representative cross-sectional study of adolescents.

Authors:  Matthew Sunderland; Katrina Champion; Tim Slade; Cath Chapman; Nicola Newton; Louise Thornton; Frances Kay-Lambkin; Nyanda McBride; Steve Allsop; Belinda Parmenter; Maree Teesson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-05-24       Impact factor: 4.328

3.  Optimising the management of children with concomitant bladder dysfunction and behavioural disorders.

Authors:  Dilharan D Eliezer; Christopher Lam; Angela Smith; John Mithran Coomarasamy; Naeem Samnakay; Malcolm R Starkey; Aniruddh V Deshpande
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-06-29       Impact factor: 5.349

4.  Moderate-to-vigorous group aerobic exercise versus group leisure activities for mild-to-moderate depression in adolescents: study protocol for a multicentre randomised controlled trial.

Authors:  Rebecca Mortazavi; Maria Lalouni; Rebecca Grudin; Eva Serlachius; Carl Johan Sundberg; Jessica Norrbom; Ingrid Larsson; Emma Haglund; Andreas Ivarsson; Fabian Lenhard; Tina Cronqvist; Kristina Ingemarsson; Åsa Mårsell; Olof Rask; Håkan Jarbin
Journal:  BMJ Open       Date:  2022-07-12       Impact factor: 3.006

5.  Characterizing Creative Thinking and Creative Achievements in Relation to Symptoms of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.

Authors:  Marije Stolte; Victoria Trindade-Pons; Priscilla Vlaming; Babette Jakobi; Barbara Franke; Evelyn H Kroesbergen; Matthijs Baas; Martine Hoogman
Journal:  Front Psychiatry       Date:  2022-07-01       Impact factor: 5.435

6.  Changes in the Prevalence of Child and Youth Mental Disorders and Perceived Need for Professional Help between 1983 and 2014: Evidence from the Ontario Child Health Study.

Authors:  Jinette Comeau; Katholiki Georgiades; Laura Duncan; Li Wang; Michael H Boyle
Journal:  Can J Psychiatry       Date:  2019-04       Impact factor: 4.356

7.  The Prevalence of Psychiatric Disorders in Children and Adolescents in Hamadan Province, West of Iran.

Authors:  Mohammad Ahmadpanah; Marzieh Nazaribadie; Mohammad Reza Mohammadi; Zahra Hooshyari; Seyyed Salman Alavi; Ali Ghaleiha; Leila Jahangard; Amir Keshavarzi; Majid Farahmand Sabet; Safdar Nabizadeh; Nafiseh Bagheri; Parvaneh Zaeri Omid; Jale Arji; Faeze Kokabi Heidarpoor; Donya Jedi Ghader; Saba Abbasi; Narges Toluei
Journal:  J Res Health Sci       Date:  2018-12-10

8.  Does the millennial generation of women experience more mental illness than their mothers?

Authors:  Jake M Najman; William Bor; Gail M Williams; Christel M Middeldorp; Abdullah A Mamun; Alexandra M Clavarino; James G Scott
Journal:  BMC Psychiatry       Date:  2021-07-17       Impact factor: 3.630

9.  A growing need for youth mental health services in Canada: examining trends in youth mental health from 2011 to 2018.

Authors:  K Wiens; A Bhattarai; P Pedram; A Dores; J Williams; A Bulloch; S Patten
Journal:  Epidemiol Psychiatr Sci       Date:  2020-04-17       Impact factor: 6.892

10.  Screening efficiency of the Mood and Feelings Questionnaire (MFQ) and Short Mood and Feelings Questionnaire (SMFQ) in Swedish help seeking outpatients.

Authors:  Håkan Jarbin; Tord Ivarsson; Markus Andersson; Hanna Bergman; Gudmundur Skarphedinsson
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.